2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.01 Neoadjuvantimmunochemotherapy Versus Chemotherapy for Elderly Patients with IB-IIIB Non-Small-Cell Lung Cancerin Real-World Practice

EP.07C.01 Neoadjuvantimmunochemotherapy Versus Chemotherapy for Elderly Patients with IB-IIIB Non-Small-Cell Lung Cancerin Real-World Practice

Back to course

Pdf Summary

This retrospective study investigated the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in elderly patients (aged 65 years or older) with stage IB-IIIB non-small-cell lung cancer (NSCLC) without driver gene mutations. Conducted at the First Affiliated Hospital, Zhejiang University School of Medicine from 2016 to 2022, the study included 140 patients, divided between an immunochemotherapy group (n=93) and a chemotherapy group (n=47).<br /><br />The primary endpoints were disease-free survival (DFS) and overall survival (OS), with secondary endpoints including objective response rate (ORR), adverse events (AEs), and pathological response. Results indicated that the immunochemotherapy group demonstrated significantly higher ORR (73.1% versus 29.8%), major pathologic response (MPR) (64.4% versus 25.8%), and a higher pathologic complete response (pCR) rate (32.2% versus 16.1%) compared to the chemotherapy group.<br /><br />Survival analysis showed a median DFS of 14.1 months for the chemotherapy group, while the median was not reached in the immunochemotherapy group. The median overall survival was 33.9 months for the chemotherapy group, whereas it was not achieved in the immunochemotherapy group, indicating potentially longer survival benefits in the latter.<br /><br />Regarding safety, adverse events were slightly higher in the immunochemotherapy group, with grade 3-4 AEs occurring in 19.4% of patients compared to 8.5% in the chemotherapy group; however, this difference was not statistically significant (P=0.156).<br /><br />In conclusion, neoadjuvant immunochemotherapy appeared to provide superior clinical outcomes in terms of survival and response rates for elderly patients with stage IB–IIIB NSCLC, without a significant increase in severe adverse events, suggesting a beneficial risk-to-reward ratio for this treatment strategy.

Asset Subtitle

Yuhong Yang

Meta Tag

Speaker Yuhong Yang

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neoadjuvant immunochemotherapy

elderly patients

non-small-cell lung cancer

NSCLC

disease-free survival

overall survival

objective response rate

adverse events

pathologic response

clinical outcomes